 Gossamer Bio NASDAQ:GOSS was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and ... 